All In Biotech

Drug Trial Radar · NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (Atigotatug+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 530 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

530

Planned (sponsor's estimate)

Start

Feb 25, 2025

Primary completion

Aug 17, 2027

Study completion Jul 14, 2031

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Conditions

  • Extensive-Stage Small Cell Lung Cancer

Interventions

  • BMS-986489 (Atigotatug+Nivolumab)Biological

    Specified dose on specified days

  • AtezolizumabBiological

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • EtoposideDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 5 years

Locations

183 sites in 26 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, PC

    Daphne, Alabama · Recruiting

  • Local Institution - 0283

    Hot Springs, Arkansas · Completed

  • Florida Cancer Specialists - South

    Fort Myers, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • Florida Cancer Specialists - North

    St. Petersburg, Florida · Recruiting

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia · Recruiting

  • Illinois Cancer Care

    Peoria, Illinois · Recruiting

  • Local Institution - 0037

    Minneapolis, Minnesota · Withdrawn

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Sanford Medical Center

    Bismarck, North Dakota · Recruiting

  • Sanford Fargo Medical Center

    Fargo, North Dakota · Recruiting

  • Oncology Hematology Care

    Cincinnati, Ohio · Recruiting

  • Sanford Cancer Center

    Sioux Falls, South Dakota · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central/South Texas

    Austin, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Tyler, Texas · Recruiting

  • Oncology & Hematology Associates of Southwest Virginia, Inc.

    Roanoke, Virginia · Recruiting

  • Swedish Cancer Institute - Edmonds

    Edmonds, Washington · Recruiting

  • Swedish Medical Center

    Seattle, Washington · Recruiting

  • Local Institution - 0079

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Completed

  • Local Institution - 0077

    ABB, Buenos Aires F.D., Argentina · Completed

  • Local Institution - 0100

    Buenos Aires, Buenos Aires F.D., Argentina · Withdrawn

  • Local Institution - 0080

    CABA, Buenos Aires F.D., Argentina · Active not recruiting

  • Local Institution - 0094

    Río Cuarto, Córdoba Province, Argentina · Active not recruiting

  • Local Institution - 0202

    Campbelltown, New South Wales, Australia · Active not recruiting

  • Local Institution - 0106

    Penrith, New South Wales, Australia · Active not recruiting

  • Local Institution - 0105

    Brisbane, Queensland, Australia · Active not recruiting

  • Local Institution - 0190

    Ballarat Central, Victoria, Australia · Completed

  • Local Institution - 0175

    Murdoch, Western Australia, Australia · Active not recruiting

  • Local Institution - 0252

    Linz, Austria · Active not recruiting

  • Local Institution - 0255

    Rankweil, Austria · Active not recruiting

  • Local Institution - 0253

    Graz, Styria, Austria · Active not recruiting

  • Local Institution - 0251

    Wels, Upper Austria, Austria · Completed

  • Local Institution - 0092

    Liège, Belgium · Active not recruiting

  • Local Institution - 0198

    Brussels, Bruxelles-Capitale, Région de, Belgium · Active not recruiting

  • Local Institution - 0091

    Ghent, Oost-Vlaanderen, Belgium · Active not recruiting

  • Local Institution - 0187

    Sint-Niklaas, Oost-Vlaanderen, Belgium · Active not recruiting

  • Local Institution - 0166

    Fortaleza, Ceará, Brazil · Active not recruiting

  • Local Institution - 0165

    Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.